Abstract：
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a relapsing demyelinating condition. There are several cross-sectional studies showing evidence of brain atrophy in people with MOGAD (pwMOGAD), but longitudinal brain volumetric assessment is still an unmet need. Current recommendations do not include monitoring with MRI and assume distinct attacks. Evidence of ongoing axon loss will have diagnostic and therapeutic implications. In this study, we assessed brain volume changes in pwMOGAD over a mean follow-up period of 2 years and compared this to changes in people with multiple sclerosis (pwMS).
This is a retrospective single-center study over a 7-year period from 2014 to 2021. MRI brain scans at the time of diagnosis and follow-up in remission were collected from 14 Caucasian pwMOGAD, confirmed by serum myelin oligodendrocyte glycoprotein immunoglobulin G antibody presence, detected by live cell-based assays. Total brain volume (TBV), white matter (WM), gray matter (GM), and demyelinating lesion volumes were assessed automatically using the Statistical Parametric Mapping and FMRIB automated segmentation tools. MRI brain scans at diagnosis and follow-up on remission were collected from 32-matched pwMS for comparison. Statistical analysis was done using analysis of variance.
There is evidence of TBV loss, affecting particularly GM, over an approximately 2-year follow-up period in pwMOGAD (p < .05), comparable to pwMS. WM and lesion volume change over the same period were not statistically significant (p > .1).
We found evidence of loss of GM and TBV over time in pwMOGAD, similar to pwMS, although the WM and lesion volumes were unchanged.
This is a retrospective single-center study over a 7-year period from 2014 to 2021. MRI brain scans at the time of diagnosis and follow-up in remission were collected from 14 Caucasian pwMOGAD, confirmed by serum myelin oligodendrocyte glycoprotein immunoglobulin G antibody presence, detected by live cell-based assays. Total brain volume (TBV), white matter (WM), gray matter (GM), and demyelinating lesion volumes were assessed automatically using the Statistical Parametric Mapping and FMRIB automated segmentation tools. MRI brain scans at diagnosis and follow-up on remission were collected from 32-matched pwMS for comparison. Statistical analysis was done using analysis of variance.
There is evidence of TBV loss, affecting particularly GM, over an approximately 2-year follow-up period in pwMOGAD (p < .05), comparable to pwMS. WM and lesion volume change over the same period were not statistically significant (p > .1).
We found evidence of loss of GM and TBV over time in pwMOGAD, similar to pwMS, although the WM and lesion volumes were unchanged.
摘要：
目的：髓磷脂少突胶质细胞糖蛋白抗体相关疾病（MOGAD）是一种复发性脱髓鞘疾病。有几项横断面研究显示MOGAD（pwMOGAD）患者存在脑萎缩的证据，但是纵向脑体积评估仍然是一个未满足的需求。目前的建议不包括MRI监测和假设不同的攻击。持续轴突损失的证据将具有诊断和治疗意义。在这项研究中,我们评估了平均2年随访期间pwMOGAD的脑体积变化,并将其与多发性硬化症(pwMS)患者的变化进行了比较.
方法：这是一项回顾性的单中心研究，为期7年，从2014年到2021年。从14名高加索人pwMOGAD收集了诊断时的MRI脑部扫描和缓解期随访，通过血清髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体的存在，通过基于活细胞的检测。总脑容量（TBV），白质（WM），灰质（GM），使用统计参数映射和FMRIB自动分割工具自动评估脱髓鞘病变体积。从32个匹配的pwMS收集诊断时的MRI脑扫描和缓解后的随访进行比较。使用方差分析进行统计学分析。
结果：有TBV损失的证据，特别是对通用汽车的影响，在pwMOGAD大约2年的随访期间（p<0.05），与pwMS相当。同期WM和病变体积变化无统计学意义(p>1)。
结论：我们发现了pwMOGAD中GM和TBV随时间而损失的证据，类似于pwMS，尽管WM和病变体积没有变化。
方法：这是一项回顾性的单中心研究，为期7年，从2014年到2021年。从14名高加索人pwMOGAD收集了诊断时的MRI脑部扫描和缓解期随访，通过血清髓鞘少突胶质细胞糖蛋白免疫球蛋白G抗体的存在，通过基于活细胞的检测。总脑容量（TBV），白质（WM），灰质（GM），使用统计参数映射和FMRIB自动分割工具自动评估脱髓鞘病变体积。从32个匹配的pwMS收集诊断时的MRI脑扫描和缓解后的随访进行比较。使用方差分析进行统计学分析。
结果：有TBV损失的证据，特别是对通用汽车的影响，在pwMOGAD大约2年的随访期间（p<0.05），与pwMS相当。同期WM和病变体积变化无统计学意义(p>1)。
结论：我们发现了pwMOGAD中GM和TBV随时间而损失的证据，类似于pwMS，尽管WM和病变体积没有变化。
